Drug Trial Radar · NCT06738836
A Study to Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C]-EDG-7500
Last checked: Nov 19, 2026Latest source record: Apr 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
8
Actual
Start
Dec 3, 2024
Primary completion
Jan 17, 2025
Study completion Jan 17, 2025
Sponsor
- Lead sponsor
- Edgewise Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 18, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to: 1. Assess the mass balance (i.e., the cumulative elimination of 14C-related material in urine and feces, compared to the administered amount of radioactive isotope) of \[14C\]-EDG-7500 following a single oral dose of EDG-7500 containing a radioactive tracer, in healthy, adult male subjects. 2. Characterize the pharmacokinetics of EDG-7500 in plasma and of 14C-related material in whole blood, plasma, urine and feces following a single oral dose of EDG-7500 containing a radioactive tracer, in healthy, adult male subjects.
Conditions
- Healthy Volunteer
Interventions
[14C]-EDG-7500Drug
Oral liquid suspension
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mass BalanceTime frame: From Day -1 through study completion (up to 19 days)
- Pharmacokinetics of EDG-7500 in plasma and 14C total radioactivity in plasma and whole blood as measured by CmaxTime frame: From Day 1 to study completion (up to 18 days)
- Pharmacokinetics of EDG-7500 in plasma and 14C total radioactivity in plasma and whole blood as measured by TmaxTime frame: From Day 1 to study completion (up to 18 days)
- Pharmacokinetics of EDG-7500 in plasma and 14C total radioactivity in plasma and whole blood as measured by T1/2Time frame: From Day 1 to study completion (up to 18 days)
- Pharmacokinetics of EDG-7500 in plasma and 14C total radioactivity in plasma and whole blood as measured by AUC0-infTime frame: From Day 1 to study completion (up to 18 days)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Pharmaron Clinical Pharmacology Center, Inc.
Baltimore, Maryland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.